United Kingdom£13,960.00+6.96%
Click any ratio for an explanation.
Revenue grew a steady +12.2% a year over the last 4 fiscal years. Profit per share grew faster (+14.8% a year), so margins are widening as it scales. Analysts expect further profit growth next year: the forward multiple is +61.6% below the trailing one.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| +14.8% | -5% → +20% | 79 | 40% | |
| +12.2% | -2% → +15% | 83 | 35% | |
| +61.6% | -10% → +30% | 100 | 25% |
The windows point in different directions (+16.6% in 3 months against -0.1% over a year), so the trend has recently turned. The last three months are stronger than the six-month picture, so momentum is building rather than fading.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| +16.6% | -20% → +20% | 92 | 35% | |
| +1.2% | -25% → +30% | 48 | 30% | |
| -0.1% | -30% → +45% | 40 | 35% |
Net debt is only 1.23x EBITDA, comfortably repayable out of ordinary earnings. Debt at 66% of equity is a normal level of leverage. The Piotroski F-Score of 9/9 confirms improving fundamentals.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| 1.2x | 3.5x → -1.0x | 50 | 30% | |
| 66% | 200% → 10% | 70 | 20% | |
| 8.6% | 0% → 15% | 57 | 15% | |
| 0.94 | 0.8x → 2.0x | 12 | 10% | |
| 9/9 | 3/9 → 8/9 | 100 | 10% | |
| 3 | 1.8 → 5.0 | 38 | 10% | |
| 8.3x | 2x → 20x | 35 | 5% |
Return on equity of 22.6% means the company earns far more on its capital than it costs to fund. About 18% of every euro of revenue survives as net profit, which points to real pricing power. ROIC of 16.0% confirms the returns are not just an effect of leverage.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| 22.6% | 5% → 35% | 59 | 30% | |
| 29.6% | 3% → 30% | 98 | 25% | |
| 17.7% | 2% → 25% | 68 | 20% | |
| 16.0% | 4% → 20% | 75 | 15% | |
| 81.9% | 15% → 60% | 100 | 10% |
At 26.5x trailing earnings investors already pay up for future growth. The forward P/E of 16.4 is lower, so expected profit growth makes it look cheaper looking ahead. Based on 75% of the inputs — the rest is not published for this instrument.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| 26.5x | 40x → 8x | 42 | 30% | |
| 16.4x | 32x → 7x | 62 | 20% | |
| 11.4x | 22x → 6x | 66 | 15% | |
| 1.71% | 0% → 6% | 29 | 10% | |
| n/a | 1.6x → 0.7x | — | 25% |
Annualised volatility of 24.3% is normal for a single share. The worst fall in the past year was -23.0%, a meaningful but ordinary correction. A beta of 0.21 means it typically moves less than the market.
| Ratio | Value | Weak → Strong | Score | Wt |
|---|---|---|---|---|
| 24.3% | 55% → 15% | 77 | 40% | |
| -23.0% | -40% → -8% | 53 | 35% | |
| 0.21 | 1.8 → 0.7 | 100 | 25% |
Source: Yahoo Finance + EODHD
Last 5 fiscal years plus the current year. Click any row for an explanation.
Recent analyst views
Loading analyst views…
Recent analyst actions
Outperform · 24 Aug 2026
- Mean target
- £15,723.74
- Target range
- £11,560.19 – £19,805.84
- Implied upside
- +12.6%
- Consensus score
- 1.58
Quarterly results
No next reporting date published yet
Dividend
Forward annual dividend 2.39 GBX; last ex-dividend 2026-08-06. Next date not yet published
Investor day
Checking public announcements…
Mergers & acquisitions
Checking public announcements…
Loading headlines…
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
astrazeneca.com